Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 7/20 | 0.35 |
| ▸ | PPARA | Q07869 | 7/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847998 | 0.74 | KDM4E (0.48) | RAB9AKDM4ENPC1PPARGPPARA | |
| SCHEMBL4845281 | 0.72 | FFAR1 (0.43) | KDM4EPPARGPPARAKDRMAPT | |
| SCHEMBL4030907 | 0.71 | PPARA (0.42) | RAB9AKDM4ENPC1PPARGPPARA | |
| SCHEMBL4029798 | 0.71 | KDM4E (0.41) | RAB9AKDM4EPPARGPPARAKDR | |
| SCHEMBL4848609 | 0.65 | TSHR (0.39) | RAB9AKDM4EPPARGPPARAFFAR1 | |
| SCHEMBL4852058 | 0.65 | FFAR1 (0.59) | PPARGPPARAKDRMAPTFFAR1 | |
| SCHEMBL8135402 | 0.64 | KDM4E (0.50) | KDM4ENPC1PPARGPPARAFFAR1 | |
| SCHEMBL1931053 | 0.64 | ALDH1A1 (0.53) | KDM4EPPARGPPARAALDH1A1HPGD | |
| SCHEMBL14089655 | 0.63 | KDM4E (0.60) | RAB9AKDM4ENPC1PPARGPPARA | |
| SCHEMBL4033223 | 0.63 | FFAR1 (0.47) | PPARGPPARAFFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | SLC5A1, AHR, ALOX5 | RAB9A 1995/4885KDM4E 1421/4885NPC1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.